SDSahera Dirajlal-Fargo

Sahera Dirajlal-Fargo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sahera Dirajlal-Fargo has a total of 184 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tablet-Based Neurocognitive Tests for Ugandan Adolescents Living With HIV: Cross-Sectional Validation Study

    by Reuben N Robbins, Angel Nanteza, Joy Louise Gumikiriza-Onoria, Anthony Santoro, Christopher M Ferraris, Christine Karungi, Daphne Tsapalas, Nana Asiedu, Courtney Kirsch, Mei Tan, et al.

    Background: Adolescents living with perinatally acquired HIV (PHIV) remain at risk of neurocognitive difficulties, yet access to valid neurocognitive tests is limited in sub-Saharan Africa (SSA), where most of this population resides. Tests that can be administered by nonspecialist personnel are culturally and linguistically appropriate for SSA’s diverse populations and are brief enough for routine use are needed to expand access, but few such tools exist. Objective: We adapted NeuroScreen , a brief tablet-based neurocognitive test battery, into Luganda and evaluated its validity and acceptability for use among Ugandan adolescents with PHIV. Methods: In this cross-sectional validation study, 100 Ugandan adolescents aged 11 to 20 years (50 with PHIV; 50 HIV-negative controls) completed the Luganda- or English-language NeuroScreen battery and a commonly used traditional test battery. Participants were recruited from an existing longitudinal cardiovascular cohort at the Joint Clinical Research Centre in Kampala, Uganda. We examined convergent validity with correlations between the 2 batteries’ individual and global z -scores, known-groups validity with unadjusted and age-adjusted group comparisons, criterion validity by examining classification agreement between the 2 batteries quantified with Cohen κ, and acceptability through self-reported technology use and ease of use. Results: NeuroScreen and the traditional battery global z -scores were strongly correlated ( r =0.75; P <.001). Correlations between tests assessing similar domains were generally small to moderate, and were strongest for processing speed, attention, and working memory. Adolescents with PHIV scored significantly lower than controls on global scores for both NeuroScreen ( P =.008) and the traditional battery ( P =.003), even after adjusting for age. Agreement between batteries in classifying participants ≤1 SD (κ=0.56) and ≤2 SD (κ=0.66) below the global z -score mean was moderate, with both batteries classifying more adolescents with PHIV than controls below these thresholds. Although fewer than half of participants (42/97, 43%) had previously used a tablet, most rated NeuroScreen as easy to use, and prior tablet experience was not independently associated with NeuroScreen performance after age adjustment. Conclusions: The Luganda-adapted NeuroScreen demonstrated convergent, known-groups, and criterion validity in Ugandan adolescents with PHIV. By delivering automated administration, automated scoring, and standardized multimedia instructions in the local language on a portable tablet, NeuroScreen addresses several persistent barriers to neurocognitive assessment in low-resource settings, including shortages of specialist personnel, the time burden of traditional batteries, and the scarcity of culturally and linguistically appropriate tools. The NeuroScreen battery was found to be highly acceptable among adolescents with little or no prior tablet experience. These findings add to a growing body of evidence supporting tablet-based assessment as a practical and scalable mobile health approach to expanding access to neurocognitive testing. Future research should evaluate test-retest reliability, sensitivity to change over time, normative benchmarks, and implementation within real-world clinical workflows.

  • Open Access

    Association of childhood adversity and depression with cardiovascular health in youth with perinatal HIV 1 in Uganda

    by Sara K. Aljohani, Shan Sun, Christine Karungi, Joy Onoria, Angel Nanteza, Curtis Dolezal, Mei Tan, Courtney Kirsch, Christopher Ferraris, Nicholas Funderburg, et al.

    While adverse childhood experiences (ACEs) are known to increase cardiovascular disease (CVD) risk, their effects among youth living with perinatally acquired HIV (YPHIV) are not well characterized. In this study, we investigated associations between ACE exposure and early CVD risk among Ugandan YPHIV and youth without perinatally acquired HIV (YWoH). In a 96-week prospective cohort, 49 YPHIV and 51 YWoH (ages 10–18) were enrolled at the Joint Clinical Research Center, Uganda. YPHIV were on antiretroviral therapy with HIV-1 RNA ≤ 400 copies/mL. The primary outcome, pulse wave velocity (PWV), defined as the 96-week-to-baseline ratio, and secondary outcomes including carotid intima-media thickness (IMT), BMI, inflammatory biomarkers, and depressive symptoms (PHQ-9) were assessed at baseline and week 96. Participants completed the ACE–International Questionnaire, PHQ-9, and socioeconomic surveys. ACE sub-scores (abuse, neglect, household dysfunction) were derived. Hierarchical clustering , performed using R, identified ACE–socioeconomic exposure patterns . Regression models with an interaction term of HIV status and ACE category or total ACE score were used to evaluate whether the association between ACE and outcomes differed by HIV status using SAS Enterprise Guide. Median age was 13 years (IQR 12–14); 48% were female. YPHIV had higher total ACE scores than YWoH (p = 0.003). Two exposure clusters were identified; cluster 2 demonstrated higher ACE exposure (p ≤ 0.001 across subdomains), a greater proportion of YPHIV (p = 0.019), increased monocyte and T-cell activation (p ≤ 0.037), higher systolic blood pressure (p = 0.040), and greater PWV progression (p = 0.047). In regression models, after adjustment for demographic, behavioral, and inflammatory factors, only neglect showed a significant interaction with HIV status, indicating greater PWV progression among YPHIV (β = 0.292, SE = 0.139, p = 0.041). ACEs, particularly neglect, were independently associated with arterial stiffness in Ugandan YPHIV. Early life stress may influence inflammation and CVD risk, highlighting the need for early interventions to mitigate long-term consequences.

  • Open Access

    NK cell dysregulation may potentiate cardiovascular disease in adolescents with perinatally acquired HIV on antiretroviral therapy

    by Mario Alles, Manuja Gunasena, Aaren Kettelhut, Kate Ailstock, Victor Musiime, Cissy Kityo, Brian Richardson, Will Mulhern, Banumathi Tamilselvan, Michael Rubsamen, et al.

    Perinatally acquired HIV (PHIV) and antiretroviral therapy (ART) can alter innate immune cells, (monocytes and natural killer [NK] cells) which are important in the pathogenesis of cardiovascular disease (CVD). We compare cardiovascular biomarkers and immune signatures between adolescents with PHIV (APHIV) on suppressive ART and HIV-unexposed, adolescents without HIV in Uganda. Carotid intima-media thickness (IMT) is increased in APHIV, suggesting a higher CVD risk. Flow cytometry analysis reveals greater activation, memory, and migratory capabilities of NK cells, and increased pro-inflammatory intermediate monocytes in APHIV, and these observations are supported by transcriptomics. Many of these innate immune cell subsets are associated with carotid IMT. Plasma oxidized-LDL (Ox-LDL) is significantly lower among APHIV, and negatively correlates with pro-inflammatory, memory-like NK subsets. We demonstrate increased uptake of Ox-LDL by macrophages in the presence of activated, memory-like NK cells in vitro, suggesting a possible mechanism for greater CVD risk in APHIV. Collectively, our data demonstrate associations between dysregulated NK cell signatures and increased CVD risk among APHIV.

  • Open Access

    Distinct Metabolic and Inflammation Signatures in Urban vs Rural Ugandan Youth With HIV on Dolutegravir

    by Sahera Dirajlal-Fargo, Shan Sun, Kate Ailstock, Morgan Cummings, Nate Lucas, Rashida Nazzinda, Christine Karungi, Daisy Faith Oryem, Robert Kidega, Victor Musiime, et al.

    Background: In sub-Saharan Africa, the majority of the metabolic data are from youth living in urban areas. In youth with perinatally acquired HIV (YPHIV) and seronegative (HIV–), we examined inflammatory and metabolic signatures in urban versus rural Uganda. Methods: YPHIV (n = 100) were enrolled from urban and rural Uganda in an observational cohort study along with age- and sex- matched, population-based HIV– (n = 99) comparators. YPHIVs were on antiretroviral with HIV-1 RNA level ≤400 copies/mL. We compared variables using Wilcoxon rank-sum tests and chi-squared tests. General linear regression models were used to assess factors associated with metabolic and inflammatory biomarkers, adjusting for HIV status, socioeconomic factors, and other covariates. Results: Median age was 16.2 years, 52% rural versus 96% urban YPHIV had HIV-RNA <50 copies/mL, 93% of YPHIV were on Tenofovir, Lamivudine, and Dolutegravir. Overall, rural participants lived in extreme poverty compared to urban participants (P < .001). Urban YPHIV were more likely to have higher body mass index, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), total cholesterol, and low-density lipoprotein than rural YPHIV (P < .001); however sCD14, sCD163, high sensitivity C-reactive protein, interleukin-6, soluble tumor necrosis factor alspha receptor I (TNFRI), and lipopolysacchiride binding protein (LBP) were higher in rural YPHIV (P ≤ .001). After adjusting for demographic, socioeconomic, viral load and antiretroviral duration, only sCD14 remained elevated in the rural YPHIV (β: 1.1; 95% confidence interval, .2–2.0), and β D glucan in urban YPHIV (β 1.11; 95% confidence interval, .3–1.89). Conclusions: The monocyte activation marker sCD14, was associated with HIV status and remained elevated in rural YPHIV even after adjusting for differences in HIV factors. Increasing the inclusion of rural populations in sub-Saharan Africa is paramount as we focus on preventing comorbidities in aging YPHIV.

  • Open Access

    Metabolic syndrome and Pathobiological Determination of Atherosclerosis in Youth risk score in adolescents with and without perinatally acquired HIV in the Cape Town Adolescent and Antiretroviral Cohort ( CTAAC )‐Heart study

    by Sahera Dirajlal‐Fargo, Mothabisi Nyathi, Shan Sun, Lauren Balmert Bonner, Morné Kahts, Nana Akua Asafu‐Agyei, Nomawethu Jele, Emma Carkeek, Justine Legbedze, Grace A. McComsey, et al.

    Background: Limited data exist describing metabolic syndrome (MetS) and Pathobiological Determinants of Atherosclerosis in Youth (PDAY) coronary arteries (CA) and abdominal aorta (AA) risk scores in youth with HIV in sub‐Saharan Africa. Methods: This cross‐sectional analysis assessed MetS and PDAY CA and AA risk scores among youth with perinatally acquired HIV, youth with non‐perinatally acquired HIV, and HIV‐seronegative youth. Elevated PDAY score was defined as ≥1. Cluster heat map analysis was used, and logistic regression models were fit to assess the association of HIV status with MetS and PDAY CA and AA risk scores separately after adjusting for covariates. Results: We enrolled 237 youth with perinatally acquired HIV, 56 youth with non‐perinatally acquired HIV and 71 HIV‐seronegative youth; median (interquartile range = IQR) age was 18 (17, 20) years, 58% females. Youth with non‐perinatally acquired HIV had the highest proportion with MetS (34%), while HIV‐seronegative youth had 23%, and youth with perinatally acquired HIV 12%. Forty‐seven percent of youth with perinatally acquired HIV, 63% of youth with non‐perinatally acquired HIV and 41% of HIV‐seronegative youth had elevated PDAY CA score; 30% of youth with perinatally acquired HIV, 39% of youth with non‐perinatally acquired HIV and 23% of HIV‐seronegative youth had elevated PDAY AA score. A non‐overweight but hyperlipidaemic phenotype predominantly comprised of youth with perinatally acquired HIV was observed by cluster analysis. Youth with perinatally acquired HIV had lower adjusted odds of MetS compared with HIV‐seronegative youth (odds ratio = 0.35, 95% confidence interval: 0.16, 0.79) but HIV status (either youth with perinatally acquired HIV or youth with non‐perinatally acquired HIV vs. HIV‐seronegative) was not associated with an elevated PDAY CA or AA risk score. Conclusion: Youth with perinatally acquired HIV have a lower odd of MetS, reflecting an overall non‐overweight, but hyperlipidaemic phenotype highlighting the need for further cardiometabolic research in this ageing population in South Africa.


  • Immune Activation Is Associated With Neurocognitive Performance in Ugandan Adolescents Living With HIV

    by Sahera Dirajlal-Fargo, Abdus Sattar, Monika Strah, Christine Karungi, Joy Louise Gumikiriza-Onoria, Anthony F. Santoro, Courtney Kirsch, Angel Nanteza, Christopher M. Ferraris, Daphne Tsapalas, et al.

    We examined relationships between neurocognition and immune activation in Ugandan adolescents with perinatally acquired HIV (PHIV). Eighty-nine adolescents in Kampala, Uganda (32 virally suppressed [+ and CD8+) activation and gut markers. Spearman rank correlations and median regressions examined associations between test performance and immune activation. The median [IQR] age was 15 [13–16] years, and 40% were girls. The median time on antiretroviral therapy was 10 years [7–11] for PHIV; 87% had viral load P = 0.05) and significantly worse on tests of executive functioning and delayed recall (P's ≤ 0.05). Overall, monocyte activation significantly correlated with worse test performance on global z-score (r = 0.21, P = 0.04), attention, processing speed, and motor speed (r = 0.2–0.3, P ≤ 0.01). T-cell activation was significantly correlated with worse performance on tests of learning, executive functioning, and working memory (r = 0.2–0.4, P ≤ 0.04). In PHIV, after adjusting for age, sex, and antiretroviral therapy duration, activated CD4 T cells remained associated with worse memory (β-0.3, 95% CI: −0.55 to −0.07, P = 0.01). PHIV with virologic suppression on antiretroviral therapy shows evidence of worse neurocognitive test performance compared with controls. Monocyte and T-cell activation is correlated with worse neurocognition in Ugandan youth with and without HIV, which has not been previously investigated in this setting.


  • Changes in the Lipidome Are Associated With Immune Activation and Subclinical Vascular Disease in Youth With Human Immunodeficiency Virus in Uganda

    by Sahera Dirajlal-Fargo, Melica Nikahd, Kate Ailstock, Manjunath Manubolu, Victor Musiime, Cissy Kityo, Grace A McComsey, Nicholas T Funderburg

    Background: This study examined the changes in the lipidome and associations with immune activation and cardiovascular disease (CVD) markers in youth with perinatally acquired human immunodeficiency virus (YPHIV). Methods: The serum lipidome was measured in antiretroviral therapy (ART)–treated YPHIV (n = 100) and human immunodeficiency virus–uninfected children (n = 98) in Uganda. Plasma markers of systemic inflammation, monocyte activation, gut integrity, and T-cell activation, as well as common carotid artery intima media thickness and pulse wave velocity (PWV), were evaluated at baseline and 96 weeks. Results: Overall, median age was 12 years, and 52% were females. Total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein were similar between the groups; however, the concentrations of ceramides, diacylglycerols, free fatty acids, lysophosphatidylcholines, and phosphatidylcholines were higher in YPHIV (P ≤ .03). Increases in phosphatidylethanolamine (16:0 and 18:0) correlated with increases in soluble CD163, oxidized LDL, C-reactive protein, intestinal fatty acid binding protein, and PWV in YPHIV (r ≥ 0.3). Conclusions: YPHIV successfully suppressed on ART have elevated lipid species that are associated with CVD, specifically palmitic acid (C16:0) and stearic acid (C18:0).


  • Gut permeability is associated with lower insulin sensitivity in youth with perinatally acquired HIV

    by Sahera Dirajlal-Fargo, Wendy Yu, Denise L. Jacobson, Ayesha Mirza, Mitchell E. Geffner, Jennifer Jao, Grace A. McComsey, for the Pediatric HIV/AIDS Cohort Study (PHACS)

    The relationships between alterations in the intestinal barrier, and bacterial translocation with the development of metabolic complications in youth with perinatally acquired HIV (YPHIV) have not been investigated. The PHACS Adolescent Master Protocol enrolled YPHIV across 15 U.S. sites, including Puerto Rico, from 2007 to 2009. For this analysis, we included YPHIV with HIV viral load 1000 c/ml or less, with at least one measurement of homeostatic assessment of insulin resistance (HOMA-IR) or nonhigh density lipoprotein (non-HDLc) between baseline and year 3 and plasma levels of intestinal fatty-acid binding protein (I-FABP), lipopolysaccharide-binding protein (LBP), and zonulin levels at baseline. We fit linear regression models using generalized estimating equations to assess the association of baseline log10 gut markers with log10 HOMA-IR and non-HDLc at all timepoints. HOMA-IR or non-HDLc was measured in 237, 189, and 170 PHIV at baseline, Yr2, and Yr3, respectively. At baseline, median age (Q1, Q3) was 12 years (10, 14), CD4+ cell count was 762 cells/μl (574, 984); 90% had HIV RNA less than 400 c/ml. For every 10-fold higher baseline I-FABP, HOMA-IR dropped 0.85-fold at baseline and Yr2. For a 10-fold higher baseline zonulin, there was a 1.35-fold increase in HOMA-IR at baseline, 1.23-fold increase in HOMA-IR at Yr2, and 1.20-fold increase in HOMA-IR at Yr3 in adjusted models. For a 10-fold higher baseline LBP, there was a 1.23-fold increase in HOMA-IR at baseline in the unadjusted model, but this was slightly attenuated in the adjusted model. Zonulin was associated with non-HDLc at baseline, but not for the other time points. Despite viral suppression, intestinal damage may influence downstream insulin sensitivity in YPHIV.